丹参酮IIA在勃起功能障碍中的研究进展
Research Progress of Tanshinone IIA in Erectile Dysfunction
摘要: 勃起功能障碍(ED)是男性常见的多因素疾病，其发病机制涉及血管内皮功能障碍，氧化应激，炎症反应和神经内分泌等疾病。丹参酮IIA (Tanshinone IIA)是从丹参中提取的主要活性成分，具有抗氧化、抗炎、改善微循环和保护血管内皮等药理作用。近年来，研究发现丹参酮IIA可以通过调节一氧化氮(NO)通路，抑制氧化应激和炎症反应来改善ED症状，但其具体机制仍有待进一步探讨。本文就丹参酮IIA的化学特性、药理作用；丹参酮IIA与勃起功能障碍的关联；丹参酮IIA治疗ED的研究进展进行如下综述，为ED的靶向治疗提供新思路。
Abstract: Erectile dysfunction (ED) is a common multifactorial disease in men, and its pathogenesis involves vascular endothelial dysfunction, oxidative stress, inflammatory response, and neuroendocrine disorders. Tanshinone IIA is the main active ingredient extracted from Salvia miltiorrhizae, which has pharmacological effects such as antioxidant, anti-inflammatory, improving microcirculation and protecting vascular endothelium. In recent years, research has shown that Tanshinone IIA can improve erectile dysfunction (ED) symptoms by modulating the nitric oxide (NO) pathway and inhibiting oxidative stress and inflammatory responses. However, the specific mechanisms still need to be further explored. This article reviews the chemical properties and pharmacological effects of Tanshinone IIA, the association between Tanshinone IIA and erectile dysfunction, and the research progress of Tanshinone IIA in treating ED, providing new ideas for targeted therapy of ED.
文章引用：谷威, 郭玉刚. 丹参酮IIA在勃起功能障碍中的研究进展[J]. 生物医学, 2025, 15(3): 473-478. https://doi.org/10.12677/hjbm.2025.153055

参考文献

[1] Ren, J., Fu, L., Nile, S.H., Zhang, J. and Kai, G. (2019) Salvia Miltiorrhiza in Treating Cardiovascular Diseases: A Review on Its Pharmacological and Clinical Applications. Frontiers in Pharmacology, 10, Article 753. [Google Scholar] [CrossRef] [PubMed]
[2] Li, Y., Elmer, G. and LeBoeuf, R.C. (2008) Tanshinone IIA Reduces Macrophage Death Induced by Hydrogen Peroxide by Upregulating Glutathione Peroxidase. Life Sciences, 83, 557-562. [Google Scholar] [CrossRef] [PubMed]
[3] Feng, J., Liu, L., Yao, F., Zhou, D., He, Y. and Wang, J. (2021) The Protective Effect of Tanshinone Iia on Endothelial Cells: A Generalist among Clinical Therapeutics. Expert Review of Clinical Pharmacology, 14, 239-248. [Google Scholar] [CrossRef] [PubMed]
[4] Zeng, X., Deng, Y., Yuan, M., He, Q., Wu, Y. and Li, S. (2022) Study on the Antioxidant Effect of Tanshinone IIA on Diabetic Retinopathy and Its Mechanism Based on Integrated Pharmacology. Evidence-Based Complementary and Alternative Medicine, 2022, Article ID: 9990937. [Google Scholar] [CrossRef] [PubMed]
[5] Jia, Z., Wen, T. and Zhang, Y. (2023) Possible Mechanisms of Treatment for Spinal Cord Injury Repair with Tanshinone IIA. Frontiers in Molecular Neuroscience, 16, Article 1277755. [Google Scholar] [CrossRef] [PubMed]
[6] Chang, C., Chu, C., Wang, C., Wu, H., Bi, K., Pang, J.S., et al. (2014) The Anti-Atherosclerotic Effect of Tanshinone IIA Is Associated with the Inhibition of TNF-α-Induced VCAM-1, ICAM-1 and CX3CL1 Expression. Phytomedicine, 21, 207-216. [Google Scholar] [CrossRef] [PubMed]
[7] Zhong, L., Ding, W., Zeng, Q., He, B., Zhang, H., Wang, L., et al. (2020) Sodium Tanshinone IIA Sulfonate Attenuates Erectile Dysfunction in Rats with Hyperlipidemia. Oxidative Medicine and Cellular Longevity, 2020, Article ID: 7286958. [Google Scholar] [CrossRef] [PubMed]
[8] Xie, F., Fu, X., Li, W., Bao, Y., Chang, F., Lu, Y., et al. (2025) Effects of Sodium Tanshinone IIA Sulfonate Injection on Pro-Inflammatory Cytokines, Adhesion Molecules and Chemokines in Chinese Patients with Atherosclerosis and Atherosclerotic Cardiovascular Disease: A Meta-Analysis of Randomized Controlled Trials. Frontiers in Cardiovascular Medicine, 12, Article 1511747. [Google Scholar] [CrossRef] [PubMed]
[9] Yang, X., Yang, W., He, S., Ye, H. and Lei, S. (2024) Danhong Formula Alleviates Endothelial Dysfunction and Reduces Blood Pressure in Hypertension by Regulating MicroRNA 24-Phosphatidylinositol 3-Kinase-Serine/Threonine Kinase-Endothelial Nitric Oxide Synthase Axis. Journal of Ethnopharmacology, 323, Article ID: 117615. [Google Scholar] [CrossRef] [PubMed]
[10] Li, J., Geng, X. and Cong, X. (2016) PGC-1α Ameliorates Angiotensinii-Induced Enos Dysfunction in Human Aortic Endothelial Cells. Vascular Pharmacology, 83, 90-97. [Google Scholar] [CrossRef] [PubMed]
[11] Li, H., Li, T., Chen, Z. and Li, L. (2022) Tanshinone IIA Reduces Pyroptosis in Rats with Coronary Microembolization by Inhibiting the TLR4/MyD88/NF-κB/NLRP3 Pathway. The Korean Journal of Physiology & Pharmacology, 26, 335-345. [Google Scholar] [CrossRef] [PubMed]
[12] Wang, N., Zhang, X., Ma, Z., Niu, J., Ma, S., Wenjie, W., et al. (2020) Combination of Tanshinone IIA and Astragaloside IV Attenuate Atherosclerotic Plaque Vulnerability in ApoE-/- Mice by Activating PI3K/AKT Signaling and Suppressing TRL4/NF-κB Signaling. Biomedicine & Pharmacotherapy, 123, Article ID: 109729. [Google Scholar] [CrossRef] [PubMed]
[13] Shang, Q., Wang, H., Li, S. and Xu, H. (2013) The Effect of Sodium Tanshinone IIA Sulfate and Simvastatin on Elevated Serum Levels of Inflammatory Markers in Patients with Coronary Heart Disease: A Study Protocol for a Randomized Controlled Trial. Evidence-Based Complementary and Alternative Medicine, 2013, Article ID: 756519. [Google Scholar] [CrossRef] [PubMed]
[14] Chen, Z., Gao, X., Jiao, Y., Qiu, Y., Wang, A., Yu, M., et al. (2019) Tanshinone IIA Exerts Anti-Inflammatory and Immune-Regulating Effects on Vulnerable Atherosclerotic Plaque Partially via the TLR4/MyD88/NF-κB Signal Pathway. Frontiers in Pharmacology, 10, Article 850. [Google Scholar] [CrossRef] [PubMed]
[15] Yang, J., Pan, Y., Ge, J., Chen, B., Mao, W., Qiu, Y., et al. (2016) Tanshinone IIA Attenuates TNF-α-Induced Expression of VCAM-1 and ICAM-1 in Endothelial Progenitor Cells by Blocking Activation of NF-κB. Cellular Physiology and Biochemistry, 40, 195-206. [Google Scholar] [CrossRef] [PubMed]

为你推荐